OBS Medical

Abingdon, UK -  19^th May 2010.  OBS Medical is delighted to announce that it has celebrated 10 years of being in business. OBS Medical was formed on 24^th March 2000 as a spin out from Oxford University, initially called Oxford Biosignals it developed signal processing solutions for the healthcare sector and algorithms for monitoring jet engines. The business was merged with t+ Medical (formerly e-San) another Oxford spin out in 2010, to offer a range of solutions for in hospital monitoring , telehealth, telecare and clinical trials. The range of well known product brands includes Visensia, t+ diabetes, BiQT and mPRO. The founder Lionel Tarassenko hosted an evening at Oxford University during a recent sales conference to mark the expansion of the sales team in the USA region at which the 10 years of OBS was celebrated. Current CEO, James Otter, said  he was very pleased with the new merged company and looked forward to more exciting opportunities in the next 10 years. For more information please contact OBS Medical, info@obsmedical.com, UK +44 (0)1235 432050: US +1 919 969 9839. Note to editors:

1. OBS Medical is an organisation focussed on improving patient outcomes through real time monitoring.  The company’s product offerings cover the whole range of health care environments from acute hospital wards to the home with benefits including reduced hospital admissions and length of stay, improved management of Long Term Conditions and improved quality of life for patients.

Abingdon, UK -  18^th March 2010.  OBS Medical is delighted to announce that Depomed Inc have selected mPRO^tm to provide a Patient Recorded Outcome system for their Breeze 3 study.  The decision by Depomed starts a new relationship with OBS Medical and and further develops an exciting initiative to use mobile phones to record patient outcomes.  The award marks a major milestone for OBS Medical in extending the use of mPRO^tm from phase 2 studies into a large scale, phase 3 clinical trial. The Breeze 3 study is a phase 3 trial of Sereda^tm, an investigational formulation of Gabapentin for the treatment of Hot Flashes in post menopausal women mPRO^tm provides a unique yet practical method of gathering electronic patient reported data on a mobile phone.  mPRO^tm has been used in a number of clinical studiers to date involving several hundred subjects. mPRO^tm enables researchers and their staff to review and analyse real time information.  It can also be a quick and effective communication tool with trial subjects. Fully customisable diaries, using adaptive branch logic are down loaded to mobile phones.  Subjects answer diary questions via their mobile phone and the data is automatically sent wirelessly to a secure server.  Researchers and staff can instantly access subjects’ real-time information and begin to quantify and qualify study trends and analysis. “mPRO^tm offers significant advantages over traditional methods of collecting information from trial subjects” says Alex Orsinski, Director, Business Development “The setup and roll out of questionnaires to subjects is fast, meaning that studies can commence more quickly and finish sooner.  Mobile phones provide a familiar and easy to use interface which boosts compliance rates, and the system offers real time information as a study progress, which means that study coordinators and researches can quickly see what is happening through the trial” For more information please contact OBS Medical, sales@obsmedical.com, UK +44 (0)1235 432050: US +1 919 969 9839. Note to editors:

1. Depomed Inc is a specialty pharmaceutical company focused on enhancing pharmaceutical products. Since its founding in August 1995, the company has advanced two products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations.
2. OBS Medical is an organisation focussed on improving patient outcomes through real time monitoring.  The company’s product offerings cover the whole range of health care environments from acute hospital wards to the home with benefits including reduced hospital admissions and length of stay, improved management of Long Term Conditions and improved quality of life for patients.